/* */ Treatment of Parkinson's disease | Health Diagnosis

Treatment of Parkinson’s disease

Parkinson's disease

At the start of treatment the symptoms respond better to different long period of time. This period is individual and depends on the shape of disease – tremor-rigid. Also of therapy. The treatment may be symptomatic or replacement by restoring the level of dopamine or dopamine receptor stimulation. Preventative treatment aims to prevent progression of the disease. In Bulgaria was adopted consensus for the treatment of early Parkinson’s disease. According to him delaying the start of treatment with levodopa. In the early stages apply MAO-B inhibitors (Selegeline) or Amantadine, that have a neuroprotective effect. These medications are usually effective the first 3-4 years of the disease. Upon depletion of the clinical effect is transferred to levodopa preparations.

Levodopa is a precursor of dopamine and thus fills the shortage of dopamine in the central nervous system. Apply together with dopa-decarboxylase inhibitors, thus achieving reduced peripheral conversion of Levodopa in Dopamin. Dopamine agonists are agents that directly affect striatal dopamine receptors. Apply in advanced Parkinson’s disease with Levodopa. Such a preparation is the medicament Pramipexol. Anticholinesterase medicine (Akineton, Parkisan) have limited application in therapy because of their significant side effects. It is assumed that they affect mainly tremor. Current therapy for Parkinson’s disease involves a medicament with a neuroprotective effect to slow the progression of the disease and the controlled release formulation of levodopa to provide optimum levels of dopamine. In case of a significant motor fluctuations associated with the intake of each single dose of the drug is taken, the patient enters the stage of late Parkinson’s disease. In this observed various complications caused by both the disease itself and from the medication.

Treatment of Parkinson’s disease is primarily based on replacement therapy insufficient dopamine production by the administration of levodopa (L.-dopa) or by simulating the effects of dopamine by administering dopa agonists such as pramipexole, ropinirole, pergolide or bromocriptine. Levodopa is open as an option for treatment of Parkinson’s disease Arvid Carlsson. Levodopa is a dopamine precursor which undergoes transformation into dopamine in the brain structures. Preventive therapy is aimed at preventing the progression of the disease by applying the compositions with a neuroprotective effect.


728x90 HealthTap